GENETICS OF RELAPSE RISK

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 拟议工作的总体目标是测试一种理论，该理论将儿茶酚-O-甲基转移酶（COMT）和γ-氨基丁酸A受体α 2（GABRA 2）基因与中间表型联系起来，进而与药物滥用复发的重要临床问题联系起来。 它将测试是否有基因已被经验联系到物质依赖，并测量额叶脑功能（即，自发脑电图中的快B功率和额叶P300 a振幅），也增加了这些疾病复发的风险。 该项目的具体目标是：（1）检查100名可卡因、海洛因或多种药物依赖患者在研究入组后4个月内恢复物质使用的基因型与100名成功维持戒断的患者和50名非物质依赖对照的基因型是否不同;（2）重复我们先前的研究结果，即与维持戒断和健康的非物质使用者相比，恢复物质使用者的脑电图（EEG）快速B活动增强，额叶P300 a振幅降低。依赖控制;（3）GABRA 2和COMT基因多态性是否分别与EEG快B波功率和额叶P300 a波幅的表型变异相关;（4）确定遗传标志物是否改善复发的预测，超过用EEG快B功率和额叶P300 a振幅获得的预测准确性，与其他已知的风险因素组合，包括依赖的严重性/慢性性，年龄，物质依赖和反社会人格障碍

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The general goal of the proposed work is to test a theory that links the Catechol-O-methyl transferase (COMT) and gamma-aminobutyric acid A receptor, alpha 2 (GABRA2) genes to intermediate phenotypes, and, in turn, to the important clinical problem of relapse to substance abuse. It will test whether genes that have been empirically linked to substance dependence, and to measures of frontal brain function (viz., fast b power in the spontaneous electroencephalogram and frontal P300a amplitude), also confer an increased risk for relapse to these disorders. The specific goals of the project are: (1) to examine whether the genotypes of 100 cocaine-, heroin, or polydrug-dependent patients who return to substance use within 4 months after study enrollment are different from those of 100 patients who successfully maintain abstinence and 50 non-substance-dependent controls; (2) to replicate our previous findings of enhanced electroencephalographic (EEG) fast b activity and reduced frontal P300a amplitude in patients who return to substance use in comparison to patients who maintain abstinence and to healthy non-substance-dependent controls; (3) to determine if polymorphisms in GABRA2 and COMT genes are respectively associated with phenotypic variation in EEG fast b power and frontal P300a amplitude; (4) to determine if genetic markers improve the prediction of relapse beyond the predictive accuracy attained with EEG fast b power and frontal P300a amplitude, in combination with other known risk factors, including severity/chronicity of dependence, age, type of substance dependence, and Antisocial Personality Disorder.